Abstract 2289P
Background
Acute myeloid leukaemias (AML) are characterised by distinct chromatin dynamics and aberrant histone methylation regulations. The reversible nature of such epigenetic modifications has become attractive for the design of new AML therapies. Histone methylation is controlled by histone methyltransferases and demethylases, and among them, LSD1 has recently gained interest and tractability with the emergence of new LSD1 inhibitor clinical candidates. Here, we describe efforts to transcriptionally and functionally define the activity of EXS74539 (‘539) - a novel potent, selective and reversible LSD1 inhibitor - as a monotherapy or in combination with AML standard of care (SoC) at the single cell level, leveraging our expertise in the use of primary AML and healthy bone marrow samples as model systems (Kornauth et al, 2022).
Methods
Using primary human material as a disease relevant model system, combined with our proprietary deep learning enabled high content imaging and image analysis platform, we explored the capacity of ‘539 to induce AML blast differentiation and/or improve first line SoC therapy potential both in primary AML samples and in non-transformed healthy bone marrow or peripheral blood mononuclear cells. Collecting baseline and treatment condition genomics and transcriptomics, we modelled the AML specific sensitivity to ‘539.
Results
Through combining single cell omics and functional response data, we demonstrate, preclinically, the capacity of ‘539 monotherapy to induce AML cell differentiation marker expression ex vivo, and the usability of ‘539 together with SoC agents. Using healthy non-transformed bone marrow and colony formation assays, we demonstrate that an adapted drug regimen limits ‘539 thrombocytopenic potential.
Conclusions
Our preclinical data demonstrated ex vivo efficacy of ‘539 against AML blast cells and supported the combinatorial potential of ‘539 with first line clinical AML treatment strategies. Leveraging the reversibility of ‘539 allowed the design of adapted drug regimens, to preserve the safety profile of this inhibitor on non-transformed healthy cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Exscientia.
Funding
Exscientia.
Disclosure
C. Boudesco, R. Okumura, M. lautizi, N. Hieger, V. Thatikonda, M. Ssenekowitsch, T. Lin, G. Fiume, R. Sehlke, T. Winkler-Penz, A. Payne, R. Paveley: Financial Interests, Personal, Full or part-time Employment: Exscientia. G.I. Vladimer: Financial Interests, Personal, Full or part-time Employment: Exscientia; Financial Interests, Personal, Stocks or ownership: Exscientia; Financial Interests, Personal, Stocks/Shares: Exscientia.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08